Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660862 · ClinicalTrials.gov registry record · Phase 4
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
A Phase 4 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT06660862: Clinical Trial Phase 4 study, sponsored by University of Chicago.
NCT06660862 is a Phase 4 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 80 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06660862, a Phase 4 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
This prospective clinical trial aims to investigate the impact of darolutamide in combination with standard-of-care androgen deprivation on physical activity, specifically step count, and its correlation with important markers of safety in vulnerable adults who screen positive by a brief geriatric assessment (GA) and metastatic hormone-sensitive prostate cancer.
Primary Outcome
To investigate the impact darolutamide in combination with ADT on the physical activity (digitally collected step count) of vulnerable adults with metastatic hormone-sensitive prostate cancer over a 6-month treatment period.
Interventions
- DRUG Darolutamide
- DRUG Physician choice Androgen Deprivation (Hormone) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-11 |
| Est. Completion | 2029-11 |
| Phase | Phase 4 |
What is known before NCT06660862 opens enrollment
NCT06660862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Darolutamide is the first listed.
NCT06660862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06660862 about?
NCT06660862 is a clinical study titled "Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.". This prospective clinical trial aims to investigate the impact of darolutamide in combination with standard-of-care androgen deprivation on physical activity, specifically step count, and its correlation with important markers of safety in vulnerable adults who screen positive by a brief geriatric a...
What is the current status of trial NCT06660862?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2026-11. Estimated completion is 2029-11.
What interventions are being tested in trial NCT06660862?
The interventions under investigation include: Darolutamide (DRUG), Physician choice Androgen Deprivation (Hormone) Therapy (DRUG).
Who is sponsoring clinical trial NCT06660862?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06660862's enrollment target sits among peer trials
80 946th of 2000 higher than 1,021 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia